People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NephroDI Therapeutics, Inc. | — | Pharmaceuticals | Seed | $3.6M | $9.8M | 2024 |
Bibhash M. Mukhopadhyay at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bibhash M. Mukhopadhyay on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Grissinger | 1 | 2 |
| Rachael Hagan | 1 | 1 |
| Jeff M. Sands, M.D. | 1 | 1 |
| Fred M. Callori | 1 | 1 |
| Chris M. Garabedian | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.